Company: DAWN
Filing Date: 2025-03-06
Form Type: 10-K/A
Source: 0000950170-25-034878
Chunk: 30

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K/A
Chunk 30
---
|:-------------|:--|
| Intangible assets with finite lives: |     |              |        |   |     |              |   |
| License agreement milestone payment  |     | $            |  9,000 |   |     | $            | — |
| PRV-related obligation payment       |     |              |  8,100 |   |     |              | — |
| Intangible assets, gross             |     |              | 17,100 |   |     |              | — |
| Less accumulated amortization        |     |              | (1,470 | ) |     |              | — |
| Intangible assets, net               |     | $            | 15,630 |   |     | $            | — |

The Company incurred amortization expense of $1.5million for the year ended December 31, 2024.

<div align='center'>F-21</div>

The estimated aggregate amortization expense for amortizable finite-lived intangible assets as of December 31, 2024 is as follows:

| Year Ending December 31,                   
 2025                                       | Estimated    
 Amortization 
 Expense      |  2,345 |
|:-------------------------------------------|:-------------|-------:|
| 2026                                       |              |  2,345 |
| 2027                                       |              |  2,345 |
| 2028                                       |              |  2,345 |
| 2029                                       |              |  2,345 |
| Thereafter                                 |              |  3,905 |
| Total future expected amortization expense | $            | 15,630 |

6. Significant Agreements Takeda asset purchase agreement On December 16, 2019, a subsidiary of the Company entered into an asset purchase agreement, or the Takeda Asset Agreement, with Millennium Pharmaceuticals, Inc., a related party and an affiliate of Takeda Pharmaceutical Company Limited, or Takeda. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary’s obligations under the Takeda Asset Agreement. Pursuant to the Takeda Asset Agreement, the Company purchased certain technology rights and know-how related to TAK-580 (which is now OJEMDA™ (tovorafenib)) that provides a new approach for treating patients with primary brain tumors or brain metastases of solid tumors. The